{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:15:34Z","timestamp":1788498934466,"version":"build-2803163510"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Identifying metabolites associated with prostate cancer (Pca) aggressiveness may elucidate mechanisms underlying disease severity. Doing so in plasma and formalin-fixed, paraffin-embedded (FFPE) tissue may accelerate discovery. In this cross-sectional pilot study, we generated hypotheses for further exploration by assessing the association between plasma metabolites and the Gleason score of individuals with Pca and by evaluating the correlation between plasma and FFPE metabolite levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We examined plasma and FFPE samples from 10 individuals with Gleason score 7 (6 3\u00a0+\u00a04, 4 4\u00a0+\u00a03) and 9 individuals with Gleason score 9 (6 4\u00a0+\u00a05, 3 5\u00a0+\u00a04) tumors from a convenience sample of 19 men with Pca. We measured the relative abundance of polar metabolites at the time of radical prostatectomy. We used linear models of log\n                      <jats:sub>2<\/jats:sub>\n                      fold changes to examine plasma metabolite levels relative to pathological tumor grade. Relationships among metabolite levels measured in plasma and FFPE tumor tissue within individuals across metabolites were examined using Pearson correlations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 18 selected plasma metabolites, which were chosen\n                      <jats:italic>a priori<\/jats:italic>\n                      because of their prior association with Pca aggressiveness, serine (\n                      <jats:italic>p<\/jats:italic>\n                      =\u00a00.0051) and ornithine (\n                      <jats:italic>p<\/jats:italic>\n                      =\u00a00.036) levels were higher in individuals with Gleason 9 than Gleason 7 Pca. After multiple testing correction, however, no associations were statistically significant. The median correlation between metabolite levels in plasma and FFPE tumor tissue was 0.45 (range: 0.40\u20130.53) for the 94 metabolites measured in both biospecimens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma serine and ornithine levels demonstrated the largest differences between individuals with Gleason 7 and Gleason 9 Pca. Metabolite levels in FFPE prostate tissue samples were moderately correlated with plasma levels. Future studies with larger sample sizes are needed to further explore the hypotheses generated by this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1743012","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:25:09Z","timestamp":1788495909000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolites from blood and formalin-fixed, paraffin-embedded tissue from participants with low- and high-grade prostate cancer: a pilot study"],"prefix":"10.3389","volume":"16","author":[{"given":"Rebecca E.","family":"Graff","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik L.","family":"Bengtsson","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung H.","family":"Suh","sequence":"additional","affiliation":[{"name":"Denali Therapeutics","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Olshen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco","place":["San Francisco, CA, United States"]},{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Y.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Surgery, John A. Burns School of Medicine, University of Hawai`i at Manoa","place":["Honolulu, HI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Allen","sequence":"additional","affiliation":[{"name":"Loyola University Medical Center","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Van Blarigan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco","place":["San Francisco, CA, United States"]},{"name":"Department of Urology, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey A.","family":"Kenfield","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Cowan","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Carroll","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Simko","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June M.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco","place":["San Francisco, CA, United States"]},{"name":"Department of Urology, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.20.4669","article-title":"Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3","volume":"27","author":"Stark","year":"2009","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.01.051","article-title":"Risk of pathologic upgrading or locally advanced disease in early prostate cancer patients based on biopsy Gleason score and PSA: a population-based study of modern patients","volume":"92","author":"Caster","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000447164","article-title":"Low-risk prostate cancer and tumor upgrading in the surgical specimen: analysis of clinical factors predicting tumor upgrading in a contemporary series of patients who were evaluated according to the modified Gleason score grading system","volume":"10","author":"Porcaro","year":"2017","journal-title":"Curr Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.04.004","article-title":"Heterogeneity in D'Amico classification-based low-risk prostate cancer: differences in upgrading and upstaging according to active surveillance eligibility","volume":"33","author":"Schiffmann","year":"2015","journal-title":"Urol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.euo.2018.06.010","article-title":"The metabolic landscape of prostate cancer","volume":"2","author":"Giunchi","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics9010021","article-title":"Metabolomics biomarkers of prostate cancer: a systematic review","volume":"9","author":"Kdadra","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/1055-9965.epi-15-1223","article-title":"Metabolomic biomarkers of prostate cancer: prediction, diagnosis, progression, prognosis, and recurrence","volume":"25","author":"Kelly","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11030181","article-title":"Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics","volume":"11","author":"Lima","year":"2021","journal-title":"Metabolites"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-16-0262","article-title":"Metabolic profiling in formalin-fixed and paraffin-embedded prostate cancer tissues","volume":"15","author":"Cacciatore","year":"2017","journal-title":"Mol Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-20-0548","article-title":"Metabolomics of prostate cancer Gleason score in tumor tissue and serum","volume":"19","author":"Penney","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.113907","article-title":"The potential role of fatty acids in prostate cancer determined by GC-MS analysis of formalin-fixed paraffin-embedded tissue samples","volume":"196","author":"Buszewska-Forajta","year":"2021","journal-title":"J Pharm BioMed Anal"},{"key":"B13","unstructured":"The Regents of the University of California"},{"key":"B14","article-title":"Assessment of small metabolites in plasma, formalin-fixed paraffin-embedded tumor and normal tissue in men with prostate cancer","volume-title":"Western Section of the American Urological Association Annual Meeting (Abstract)","author":"Suh","year":"2018"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22704","article-title":"Metabolomic signatures of aggressive prostate cancer","volume":"73","author":"McDunn","year":"2013","journal-title":"Prostate"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btn506","article-title":"A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry","volume":"24","author":"Osl","year":"2008","journal-title":"Bioinformatics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.8b00926","article-title":"Preoperative metabolic signatures of prostate cancer recurrence following radical prostatectomy","volume":"18","author":"Clendinen","year":"2019","journal-title":"J Proteome Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12916-017-0885-6","article-title":"Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition","volume":"15","author":"Schmidt","year":"2017","journal-title":"BMC Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024143","article-title":"Plasma free amino acid profiling of five types of cancer patients and its application for early detection","volume":"6","author":"Miyagi","year":"2011","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m116.771931","article-title":"Leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial-mesenchymal transition","volume":"292","author":"Luo","year":"2017","journal-title":"J Biol Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23263","article-title":"Prostate cancer cells in different androgen receptor status employ different leucine transporters","volume":"77","author":"Otsuki","year":"2017","journal-title":"Prostate"},{"key":"B22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12964-019-0400-0","article-title":"EGF-activated PI3K\/Akt signalling coordinates leucine uptake by regulating LAT3 expression in prostate cancer","volume":"17","author":"Zhang","year":"2019","journal-title":"Cell Commun Signal"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16775","article-title":"Prospective serum metabolomic profile of prostate cancer by size and extent of primary tumor","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29576","article-title":"Metabolomic analysis of prostate cancer risk in a prospective cohort: the alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study","volume":"137","author":"Mondul","year":"2015","journal-title":"Int J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.euo.2019.07.005","article-title":"Plasma metabolomic profiles and risk of advanced and fatal prostate cancer","volume":"4","author":"Wang","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2014.02.004","article-title":"Serine and glycine metabolism in cancer","volume":"39","author":"Amelio","year":"2014","journal-title":"Trends Biochem Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nature11743","article-title":"Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells","volume":"493","author":"Maddocks","year":"2013","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-019-02261-8","article-title":"The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer","volume":"51","author":"Selvi","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.02.032","article-title":"Cellular metabolism and disease: what do metabolic outliers teach us","volume":"148","author":"DeBerardinis","year":"2012","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071814","article-title":"Human prostate cancer is characterized by an increase in urea cycle metabolites","volume":"12","author":"Franko","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.08.005","article-title":"The context-specific roles of urea cycle enzymes in tumorigenesis","volume":"81","author":"Hajaj","year":"2021","journal-title":"Mol Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165841","article-title":"Reprogramming of serine, glycine and one-carbon metabolism in cancer","volume":"1866","author":"Li","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2013.02.008","article-title":"Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection","volume":"80","author":"di Salvo","year":"2013","journal-title":"Med Hypotheses"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.1218595","article-title":"Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation","volume":"336","author":"Jain","year":"2012","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.393","article-title":"Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells","volume":"4","author":"Tedeschi","year":"2013","journal-title":"Cell Death Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12885-020-06908-z","article-title":"Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status","volume":"20","author":"Dudka","year":"2020","journal-title":"BMC Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24145","article-title":"Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7","volume":"81","author":"Falegan","year":"2021","journal-title":"Prostate"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1767","article-title":"Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer","volume":"7","author":"Gumulec","year":"2018","journal-title":"Cancer Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32218","article-title":"Prospective serum metabolomic profiling of lethal prostate cancer","volume":"145","author":"Huang","year":"2019","journal-title":"Int J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.305","article-title":"Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial","volume":"115","author":"Huang","year":"2016","journal-title":"Br J Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1593\/neo.13314","article-title":"The role of sarcosine metabolism in prostate cancer progression","volume":"15","author":"Khan","year":"2013","journal-title":"Neoplasia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgt176","article-title":"Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial","volume":"34","author":"Koutros","year":"2013","journal-title":"Carcinogenesis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1021\/pr5011108","article-title":"Metabolomics-derived prostate cancer biomarkers: fact or fiction","volume":"14","author":"Kumar","year":"2015","journal-title":"J Proteome Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1038\/s41598-020-60616-z","article-title":"Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt161","article-title":"Subpathway-GM: identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways","volume":"41","author":"Li","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.1c00943","article-title":"Rapid diagnosis of prostate cancer disease progression using paper spray ionization mass spectrometry","volume":"93","author":"Mahmud","year":"2021","journal-title":"Anal Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11306-020-01694-y","article-title":"Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score","volume":"16","author":"Markin","year":"2020","journal-title":"Metabolomics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6370","article-title":"Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer","volume":"7","author":"Meller","year":"2016","journal-title":"Oncotarget"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2014-5068","article-title":"1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling","volume":"10","author":"Mondul","year":"2014","journal-title":"Metabolomics"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.173179","article-title":"Preclinical evaluation of (11)C-sarcosine as a substrate of proton-coupled amino acid transporters and first human application in prostate cancer","volume":"58","author":"Piert","year":"2017","journal-title":"J Nucl Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.0c00006","article-title":"Rapid prostate cancer noninvasive biomarker screening using segmented flow mass spectrometry-based untargeted metabolomics","volume":"19","author":"Pinto","year":"2020","journal-title":"J Proteome Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cels.2017.12.014","article-title":"A landscape of metabolic variation across tumor types","volume":"6","author":"Reznik","year":"2018","journal-title":"Cell Syst"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2017.03.005","article-title":"Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: a preliminary investigation","volume":"5","author":"Roberts","year":"2017","journal-title":"Prostate Int"},{"key":"B55","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ijc.31313","article-title":"Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer","volume":"143","author":"Shao","year":"2018","journal-title":"Int J Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature07762","article-title":"Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression","volume":"457","author":"Sreekumar","year":"2009","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022486","article-title":"Serum methionine metabolites are risk factors for metastatic prostate cancer progression","volume":"6","author":"Stabler","year":"2011","journal-title":"PloS One"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014175","article-title":"Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol","volume":"5","author":"Thysell","year":"2010","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.12659\/msm.909949","article-title":"The urinary sarcosine\/creatinine ratio is a potential diagnostic and prognostic marker in prostate cancer","volume":"24","author":"Wang","year":"2018","journal-title":"Med Sci Monit"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.10.046","article-title":"NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer","volume":"501","author":"Zheng","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.0c00282","article-title":"Distinct metabolic signatures of hormone-sensitive and castration-resistant prostate cancer revealed by a (1)H NMR-based metabolomics of biopsy tissue","volume":"19","author":"Zheng","year":"2020","journal-title":"J Proteome Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025357","article-title":"Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC\/MS\/MS: application in sarcoma","volume":"6","author":"Kelly","year":"2011","journal-title":"PloS One"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2012.024","article-title":"A positive\/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue","volume":"7","author":"Yuan","year":"2012","journal-title":"Nat Protoc"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmsacl.2021.10.004","article-title":"The effect of sample age on the metabolic information extracted from formalin-fixed and paraffin embedded tissue samples using desorption electrospray ionization mass spectrometry imaging","volume":"22","author":"Isberg","year":"2021","journal-title":"J Mass Spectrom Adv Clin Lab"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2019.4898","article-title":"UPLC\u2011MS\/MS\u2011based metabolomic characterization and comparison of pancreatic adenocarcinoma tissues using formalin\u2011fixed, paraffin\u2011embedded and optimal cutting temperature6\u2011embedded materials","volume":"55","author":"Feng","year":"2019","journal-title":"Int J Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-19-1091","article-title":"Metabolic profiling of formalin-fixed paraffin-embedded tissues discriminates normal colon from colorectal cancer","volume":"18","author":"Arima","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/path.4560","article-title":"High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from formalin-fixed, paraffin-embedded clinical tissue samples","volume":"237","author":"Buck","year":"2015","journal-title":"J Pathol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2016.081","article-title":"High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue","volume":"11","author":"Ly","year":"2016","journal-title":"Nat Protoc"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11090597","article-title":"Lipidomic analysis of archival pathology specimens identifies altered lipid signatures in ovarian clear cell carcinoma","volume":"11","author":"Mir","year":"2021","journal-title":"Metabolites"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-021-00612-7","article-title":"A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer","volume":"101","author":"Neumann","year":"2021","journal-title":"Lab Invest"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2015.09.021","article-title":"Detection of metabolites discriminating subtypes of thyroid cancer: molecular profiling of FFPE samples using the GC\/MS approach","volume":"417","author":"Wojakowska","year":"2015","journal-title":"Mol Cell Endocrinol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1743012\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:25:11Z","timestamp":1788495911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1743012\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":71,"alternative-id":["10.3389\/fonc.2026.1743012"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1743012","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1743012"}}